CN109001326B - 一种地克珠利对映体手性色谱分离分析方法 - Google Patents
一种地克珠利对映体手性色谱分离分析方法 Download PDFInfo
- Publication number
- CN109001326B CN109001326B CN201810898981.4A CN201810898981A CN109001326B CN 109001326 B CN109001326 B CN 109001326B CN 201810898981 A CN201810898981 A CN 201810898981A CN 109001326 B CN109001326 B CN 109001326B
- Authority
- CN
- China
- Prior art keywords
- diclazuril
- chiral
- lower alcohol
- chromatographic separation
- hexane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZSZFUDFOPOMEET-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-[2,6-dichloro-4-(3,5-dioxo-1,2,4-triazin-2-yl)phenyl]acetonitrile Chemical class C1=CC(Cl)=CC=C1C(C#N)C1=C(Cl)C=C(N2C(NC(=O)C=N2)=O)C=C1Cl ZSZFUDFOPOMEET-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 238000013375 chromatographic separation Methods 0.000 title claims abstract description 26
- 238000004458 analytical method Methods 0.000 title claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 47
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 230000005526 G1 to G0 transition Effects 0.000 claims abstract description 24
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims abstract description 24
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000005406 washing Methods 0.000 claims abstract description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 6
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 6
- 229960004853 betadex Drugs 0.000 claims abstract description 6
- 238000004811 liquid chromatography Methods 0.000 claims abstract description 6
- 229960000248 diclazuril Drugs 0.000 claims description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000000825 ultraviolet detection Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- SBTVLCPCSXMWIQ-UHFFFAOYSA-N (3,5-dimethylphenyl) carbamate Chemical compound CC1=CC(C)=CC(OC(N)=O)=C1 SBTVLCPCSXMWIQ-UHFFFAOYSA-N 0.000 abstract description 6
- 239000011248 coating agent Substances 0.000 abstract description 6
- 238000000576 coating method Methods 0.000 abstract description 6
- 229920000856 Amylose Polymers 0.000 abstract description 3
- 229920002678 cellulose Polymers 0.000 abstract description 3
- 239000001913 cellulose Substances 0.000 abstract description 3
- 238000000926 separation method Methods 0.000 description 23
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000005760 Difenoconazole Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- -1 triazine phenylacetonitrile compounds Chemical class 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229960003376 levofloxacin Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000001165 anti-coccidial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- DSTZLNOPNQSCLE-UHFFFAOYSA-N ethanol;hexane;2,2,2-trifluoroacetic acid Chemical compound CCO.CCCCCC.OC(=O)C(F)(F)F DSTZLNOPNQSCLE-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229960002957 praziquantel Drugs 0.000 description 2
- FSVJFNAIGNNGKK-KRWDZBQOSA-N (11br)-2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1h-pyrazino[2,1-a]isoquinolin-4-one Chemical compound N1([C@H](C2=CC=CC=C2CC1)C1)C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-KRWDZBQOSA-N 0.000 description 1
- FSVJFNAIGNNGKK-QGZVFWFLSA-N (11bs)-2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1h-pyrazino[2,1-a]isoquinolin-4-one Chemical compound N1([C@@H](C2=CC=CC=C2CC1)C1)C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-QGZVFWFLSA-N 0.000 description 1
- 241000198596 Alternaria tomatophila Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000123650 Botrytis cinerea Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 241000179199 Eimeria mitis Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000519856 Phyllosticta Species 0.000 description 1
- 241000813090 Rhizoctonia solani Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- BQYJATMQXGBDHF-UHFFFAOYSA-N difenoconazole Chemical compound O1C(C)COC1(C=1C(=CC(OC=2C=CC(Cl)=CC=2)=CC=1)Cl)CN1N=CN=C1 BQYJATMQXGBDHF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000507 endocrine disrupting Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- BJTZQANDAMBQRV-UHFFFAOYSA-N hexane;propan-2-ol;2,2,2-trifluoroacetic acid Chemical compound CC(C)O.CCCCCC.OC(=O)C(F)(F)F BJTZQANDAMBQRV-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种地克珠利对映体手性色谱分离分析方法,所述分离分析方法包括如下步骤:将手性固定相预处理,以正己烷、三氟乙酸和低级醇为流动相,进行液相色谱分离分析;所述预处理是用流动相冲洗手性固定相,冲洗时间不少于2小时,冲洗流速不大于0.5 mL·min‑1;所述手性固定相为键合型对氯‑苯氨基甲酰化β‑环糊精、涂覆型纤维素三(3,5‑二甲基苯氨基甲酸酯)或涂覆型直链淀粉三(3,5‑二甲基苯氨基甲酸酯);所述低级醇为乙醇、正丙醇、异丙醇或正丁醇;所述正己烷和低级醇的体积比为50~80∶50~20。本发明提供的手性色谱分离分析方法将所述手性固定相预处理,以正己烷、三氟乙酸和低级醇为流动相,实现了地克珠利对映体的手性色谱分离。
Description
技术领域
本发明属于手性色谱分离技术领域,更具体地,涉及一种地克珠利对映体手性色谱分离分析方法。
背景技术
随着立体化学的发展,手性药物的立体选择性研究备受关注。具有相同物理化学性质的手性异构体在生物体内可能表现出截然不同的吸收、代谢、药理作用、致畸、致癌、致突变和内分泌干扰活性等性质。苯醚甲环唑的4种立体异构体对番茄早疫病菌、灰霉病菌、叶霉病菌、水稻纹枯病菌和西瓜炭疽病菌等的抑菌活性存在显著的差异,即(R,S)-苯醚甲环唑优于(R,R)-苯醚甲环唑、(S,R)-苯醚甲环唑、(S,S)-苯醚甲环唑[EnvironmentalScience&Technology,2013,47(7):3386-3394]。在广谱抗蠕虫药吡喹酮中,(R)-异构体具有抗寄生虫作用,可使虫体皮层受到破坏并引起肌肉麻痹性收缩,而(S)-异构体不具抗虫活性[Chinese Journal of Parasitology and Parasitic Diseases,1998,16(5):335-341];此外,(S)-吡喹酮对小鼠的急性半数致死量低于消旋吡喹酮和(R)-吡喹酮,表现较强的毒性[四川寄生虫科学杂志,1988,4:35-35]。左氧氟沙星的抗菌活性是右氧氟沙星的8~12倍,对多数肠杆菌科细菌有效,抗菌谱广、抗菌作用强,而右氧氟沙星几乎没有抗菌活性[New England Journal of Medicine,1991,324(6):384-394]。
地克珠利(Diclazuril)属于三嗪苯乙腈化合物,含有一个手性碳中心,有两种对映异构体(见式I),化学名称为2,6-二氯-α-(4-氯苯基)-4-(4,5-二氢-3,5-二氧代-1,2,4-三嗪)-2(3H)-苯乙腈。该药最早由比利时杨森制药厂开发,并以杀球灵为商品名在英国、德国等43个国家上市。地克珠利是一种高效、低毒的抗球虫药物,以饲料添加剂的形式用于禽类,可以有效预防和杀灭多种原虫,对所有感染鸡、火鸡和其他鸟类的致病性艾美尔球虫等有效,特别是对柔嫩、堆型、布氏、巨型和缓艾美尔球虫的抗球虫指数均超过180[Veterinary Parasitology,2003,116(4):305-314;中国兽医杂志,2009,45(6):27-28]。此外,地克珠利对兔、牛和羊的球虫感染表现出良好的抗虫效果[畜牧与兽医,2015,47(10):121-123;中国兽医寄生虫病,2007,15(3):15-17;Small Ruminant Research,2013,110(2-3):93-95]。
地克珠利因其高效、广谱及低毒的特点被广泛地使用,然而,过度使用会使动物体产生日趋严重的抗药性,同时药物在动物体内的残留增加了人类的危害。目前,主要采用液相色谱法[分析实验室,2014,33(4):420-423]和液质联用法[Chromatographia,2012,75(11-12):645-653]检测动物体及组织样品(如鸡肉、鸡蛋、猪肉、兔肉和牛奶等)中的地克珠利。然而,尚未见在手性色谱柱上对地克珠利对映体进行液相色谱手性分离技术的相关报道。
因此,开发一种手性色谱分离分析技术对于地克珠利的手性拆分和对映异构体的分析检测具有积极意义。
发明内容
本发明的目的在于弥补现有技术中地克珠利对映体手性分析分离方法的不足,提供一种地克珠利对映体手性色谱分离分析方法。
为实现上述发明目的,本发明采用如下技术方案:
一种地克珠利对映体的手性色谱分离分析方法,包括如下步骤:将手性固定相预处理,以正己烷、三氟乙酸和低级醇为流动相,进行液相色谱分离分析;
所述预处理是用流动相冲洗手性固定相,冲洗时间不少于2小时,冲洗流速不大于0.5mL·min-1;
所述手性固定相为键合型对氯-苯基氨基甲酰化β-环糊精、涂覆型纤维素三(3,5-二甲基苯基氨基甲酸酯)或涂覆型直链淀粉三(3,5-二甲基苯基氨基甲酸酯);
所述低级醇为乙醇、正丙醇、异丙醇或正丁醇;
所述正己烷和低级醇的体积比为50~80∶50~20。
发明人发现,以含三氟乙酸的正己烷-低级醇的混合溶液(50~80∶50~20,V/V)为流动相,在上述手性固定相上,能够实现地克珠利对映体的手性色谱分离。预处理步骤的目的,是使手性固定相上带有合适量的三氟乙酸,如果不进行预处理,是无法实现对地克珠利进行手性分离的。
优选地,所述手性固定相为键合型对氯-苯基氨基甲酰化β-环糊精。
优选地,所述低级醇为乙醇或正丙醇。
最优选地,所述低级醇为乙醇。
优选地,所述三氟乙酸的体积百分数为0.1%~0.3%。
优选地,所述正己烷和低级醇的体积比为60∶40。
优选地,所述地克珠利的浓度不大于1.0mg·mL-1。
更优选地,所述地克珠利的浓度为0.5mg·mL-1。
优选地,所述色谱分离分析方法中流动相的流速为1.0mL·min-1,进样体积为10μL,紫外检测波长为280nm。
更优选地,一种地克珠利对映体的手性色谱分离分析方法,包括如下步骤:将地克珠利溶解在N,N-二甲基甲酰胺和乙醇的混合溶液中,地克珠利的浓度为0.5mg·mL-1,采用键合型对氯-苯基氨基甲酰化β-环糊精手性固定相进行手性分离;所述流动相由正己烷、三氟乙酸和乙醇组成,其中,正己烷和乙醇的体积比为60∶40,并添加总体积0.1%三氟乙酸;使用前,用流动相冲洗手性固定相2~3小时,冲洗流速为0.5mL·min-1。使用时,色谱条件中流动相的流速为1.0mL·min-1,进样体积为10μL,紫外检测波长为280nm。在上述色谱条件下,地克珠利对映体间的分离度为3.23,选择因子为1.24。
与现有技术相比,本发明具有如下有益效果:
本发明首次对地克珠利对映体进行手性色谱分离分析。将本发明公开的手性固定相预处理,结合所述的正己烷、三氟乙酸和低级醇为流动相,实现了地克珠利对映体的手性色谱分离。
在优选的色谱条件下,地克珠利对映体间的分离度为3.23,选择因子为1.24。该手性色谱分离分析方法中,地克珠利对映体分离效果好,分析速度快,可应用在地克珠利对映体的分析检测和分离制备中。
附图说明
图1为本发明实施例1得到的地克珠利的HPLC谱图。
图2为本发明实施例1得到的地克珠利的HPLC谱图(以旋光检测器替代紫外检测器)。
图3为本发明实施例1~3得到的地克珠利的HPLC谱图。
图4为本发明实施例1、4~6得到的地克珠利的HPLC谱图。
图5为本发明实施例1、7~9得到的地克珠利的HPLC谱图。
具体实施方式
下面结合具体实施方式对本发明作进一步的说明,但本发明的实施方式不限于此。实施例中的原料均可通过市售得到;除非特别说明,本发明采用的试剂、方法和设备为本技术领域常规试剂、方法和设备。
在实施例中,所用的键合型对氯-苯基氨基甲酰化β-环糊精手性固定相(SCDP)、涂覆型纤维素三(3,5-二甲基苯基氨基甲酸酯)手性固定相(OD)、涂覆型直链淀粉三(3,5-二甲基苯基氨基甲酸酯)手性固定相(AD)均由广州研创生物技术发展有限公司生产,也可以使用其它公司生产的产品。
实施例1~14中地克珠利对映体的手性色谱分离分析方法
各实施例提供的地克珠利对映体手性色谱分离分析方法的具体步骤为:将地克珠利溶解于N,N-二甲基甲酰胺中,配制成5.0mg·mL-1的溶液,再用乙醇稀释至0.5mg·mL-1,控制流动相组成、流动相流速及色谱柱柱温等条件后对地克珠利进行色谱分离。
实施例1~14的手性色谱分离分析方法中,选用的色谱仪为安捷伦1200系列液相色谱仪,检测器为安捷伦1260型紫外检测器和德国CHIRALYSER-MP旋光检测器,色谱柱为广州研创生物技术发展有限公司生产的SCDP、OD和AD色谱柱,色谱柱规格均为250mm×4.6mm,使用前,用相应的流动相冲洗手性固定相2~3小时,冲洗流速为0.5mL·min-1。使用时,流动相流速为1.0mL·min-1,地克珠利样品的浓度为0.5mg·mL-1,进样体积为10μL,紫外检测波长为280nm。
表1为实施例1~3中地克珠利对映体在所选三种手性固定相上的分离结果,所选用的流动相为正己烷∶三氟乙酸∶乙醇=60:0.1:40的混合溶液,色谱柱温度为25℃。
图1为实施例1得到的地克珠利对映体HPLC谱图。地克珠利样品分别在8.99min和10.94min观察到2个色谱峰,分离度为3.18,两种对映体实现了完全分离。在相同色谱条件下,以旋光检测器替代紫外检测器亦可得到其液相色谱图(见图2),地克珠利在9.15min和11.14min出现2个色谱峰;其中,先洗脱的异构体旋光值为负值,即为(-)-地克珠利,而后洗脱的异构体则为(+)-地克珠利。
图3为实施例1~3得到手性分离地克珠利对映体的HPLC谱图。相同条件下,地克珠利对映体在所选的三种手性固定相SCDP、OD及AD上实现基线分离(Rs>1.50)。对比分离度可知,SCDP对地克珠利的分离度最大,达到3.18;对比保留时间发现,地克珠利在SCDP上的保留时间最短(t1,8.99min),而在AD上的保留时间最长(t1,20.84min),且理论塔板数最低。因此,优选SCDP作为液相色谱分离分析地克珠利的手性固定相。
表1实施例1-3中地克珠利对映体在所选手性固定相上的分离结果
表2实施例4~14的色谱分离分析方法的条件设置和分离结果
图4为实施例1、4~6得到的地克珠利对映体的HPLC谱图。在四种流动相中,地克珠利均可实现完全分离。地克珠利在正己烷-乙醇-三氟乙酸混合溶液的流动相中保留能力最弱,其分离度(Rs=3.18)大于正己烷-正丙醇-三氟乙酸混合溶液、正己烷-异丙醇-三氟乙酸混合溶液和正己烷-正丁醇-三氟乙酸混合溶液。综合考虑容量因子、选择因子及分离度,优选正己烷-乙醇-三氟乙酸混合溶液作为流动相。
图5为实施例1、7~9得到的地克珠利对映体的HPLC谱图。由图可知,在不同体积比的流动相中,随着低级醇含量的减少,地克珠利的分离度逐渐增大,保留时间增长。当正己烷∶三氟乙酸∶低级醇=80:0.1:20时,分离度达到4.10,但此时地克珠利对映体的洗脱时间显著高于其他比例,且流动相中正己烷含量过高不利于地克珠利的溶解。因此,从地克珠利的洗脱效果和溶解度等方面综合考虑,优选流动相中正己烷与低级醇的体积比为60:40。
实施例1、10~14的研究结果表明:随着色谱柱温度从15℃逐步升高到40℃,地克珠利在色谱柱上保留能力逐渐变弱,容量因子k1从2.07减小到1.47,变化较明显,但分离度和选择因子的变化不大。
显然,本发明的上述实施例仅仅是为清楚地说明本发明所作的举例,而并非是对本发明的实施方式的限定。对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明权利要求的保护范围之内。
Claims (3)
1.一种地克珠利对映体手性色谱分离分析方法,其特征在于,所述分离分析方法包括如下步骤:
将地克珠利溶解在N, N-二甲基甲酰胺和乙醇的混合溶液中,地克珠利的浓度为0.5mg×mL-1,
将手性固定相预处理,以正己烷、三氟乙酸和低级醇为流动相,进行液相色谱分离分析;
所述预处理是用流动相冲洗手性固定相,冲洗时间不少于2小时,冲洗流速不大于0.5mL×min-1;
所述手性固定相为键合型对氯-苯基氨基甲酰化β-环糊精;
所述低级醇为乙醇、正丙醇、异丙醇或正丁醇;
所述正己烷和低级醇的体积比为50~80:50~20;
所述液相色谱分离分析方法中流动相的流速为1.0 mL×min-1,进样体积为10μL,紫外检测波长为280 nm。
2.根据权利要求1所述地克珠利对映体手性色谱分离分析方法,其特征在于,所述低级醇为乙醇或正丙醇。
3.根据权利要求1所述地克珠利对映体手性色谱分离分析方法,其特征在于,所述正己烷和低级醇的体积比为60:40。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810898981.4A CN109001326B (zh) | 2018-08-08 | 2018-08-08 | 一种地克珠利对映体手性色谱分离分析方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810898981.4A CN109001326B (zh) | 2018-08-08 | 2018-08-08 | 一种地克珠利对映体手性色谱分离分析方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109001326A CN109001326A (zh) | 2018-12-14 |
| CN109001326B true CN109001326B (zh) | 2021-11-26 |
Family
ID=64596270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810898981.4A Active CN109001326B (zh) | 2018-08-08 | 2018-08-08 | 一种地克珠利对映体手性色谱分离分析方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109001326B (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016054338A1 (en) * | 2014-10-01 | 2016-04-07 | Omnigen Reserch, Llc | Compositions and combinations for use as food supplements for animals |
-
2018
- 2018-08-08 CN CN201810898981.4A patent/CN109001326B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016054338A1 (en) * | 2014-10-01 | 2016-04-07 | Omnigen Reserch, Llc | Compositions and combinations for use as food supplements for animals |
Non-Patent Citations (3)
| Title |
|---|
| Cellulose and Cellulose Derived Phases;J. Dingenen et al.;《CHIRAL SEPARATIONS》;20001231;第2299页右栏至第2301页 * |
| 地克珠利在健康鸡及球虫感染鸡体内;文丽 等;《中国兽药杂志》;20081231;第42卷(第1期);全文 * |
| 鸡组织中地克珠利和妥曲珠利残留HPLC检测方法的建立;施祖灏 等;《中国兽医学报》;20091231;第29卷(第1期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109001326A (zh) | 2018-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Horie et al. | Simultaneous determination of benofloxacin, danofloxacin, enrofloxacin and ofloxacin in chicken tissues by high-performance liquid chromatography | |
| Suzuki et al. | Identification of pectenotoxin-11 as 34 S-hydroxypectenotoxin-2, a new pectenotoxin analogue in the toxic dinoflagellate Dinophysis acuta from New Zealand | |
| Dimitrova et al. | Pharmacokinetics of enrofloxacin in turkeys | |
| CN102062758B (zh) | 克林霉素磷酸酯的杂质分析制备方法 | |
| Czyrski | Analytical methods for determining third and fourth generation fluoroquinolones: A review | |
| CN102439012A (zh) | 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法 | |
| Padivitage et al. | Enantiomeric separations of illicit drugs and controlled substances using cyclofructan‐based (LARIHC) and cyclobond I 2000 RSP HPLC chiral stationary phases | |
| CN109001326B (zh) | 一种地克珠利对映体手性色谱分离分析方法 | |
| CN103123342A (zh) | 克林霉素的杂质分析制备方法 | |
| ALOthman et al. | HPLC enantio-separation and chiral recognition mechanism of quinolones on vancomycin CSP | |
| CN102477052A (zh) | 一种提取安普霉素的方法 | |
| Pan et al. | Preparative separation of isoquinoline alkaloids from Corydalis impatiens using a middle‐pressure chromatogram isolated gel column coupled with two‐dimensional liquid chromatography | |
| Xu et al. | Benzylisoquinoline Alkaloids from Gnetum p arvifolium | |
| Tóth et al. | Liquid chromatographic method for the simultaneous determination of achiral and chiral impurities of dapoxetine in approved and counterfeit products | |
| Tsai et al. | Tetrodotoxin in several species of xanthid crabs in southern Taiwan | |
| Rebizi et al. | Chiral separation and determination of enantiomeric purity of the pharmaceutical formulation of cefadroxil using coated and immobilized amylose-derived and cellulose-derived chiral stationary phases | |
| Huang et al. | HPLC semi‐preparative separation of diclazuril enantiomers and racemization in solution | |
| Du et al. | Serratiomycins D1–D3, antibacterial cyclic peptides from a serratia sp. and structure revision of serratiomycin | |
| Cirilli et al. | Direct HPLC enantioseparation of chiral aptazepine derivatives on coated and immobilized polysaccharide‐based chiral stationary phases | |
| Wilson et al. | A preparative chiral separation of hydroxychloroquine using supercritical fluid chromatography | |
| CN112798712B (zh) | 一种二氢槲皮素对映体的手性色谱分离分析方法 | |
| CN113702517A (zh) | 甲磺酸帕珠沙星原料药中小极性杂质的检测方法 | |
| Pesek et al. | Analysis of glucosamine using aqueous normal phase chromatography | |
| Farahat et al. | An ecofriendly green liquid chromatographic method for simultaneous determination of Amoxicillin, Metronidazole and Ciprofloxacin; application to dosage form and human urine | |
| Ho et al. | Paralytic toxins in four species of coral reef crabs from Kenting National Park in southern Taiwan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |